CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Intellia Therapeutics, Inc.  (NTLA)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
 
 

NTLA's Revenue Year on Year Growth by Quarter and Year

Intellia Therapeutics,'s Revenue results by quarter and year



Select the Comparisons : Select the Ratio:                        
NTLA Revenue (in millions $) FY 2017 FY 2016 FY 2015 FY 2014
IV Quarter December - 5.63 0.00 0.00
III Quarter September - 4.87 0.00 0.00
II Quarter June - 4.21 0.00 0.00
I Quarter March 6.22 1.78 0.00 0.00
FY   6.22 16.49 - -

Financial Statements
Intellia Therapeutics,'s first quarter 2017 Revenue $ 6.22 millions NTLA's Income Statement
Intellia Therapeutics,'s first quarter 2016 Revenue $ 1.78 millions Quarterly NTLA's Income Statement
NTLA's Growth by Division See NTLA's Growth by Segment

NTLA Revenue ( Y/Y Growth %) 2017
2016 2015 2014
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March 249.16 % - - -
FY   - - - -



NTLA Revenue Growth Comment
Intellia Therapeutics, Inc. reported Revenue surge of 249.16% year on year in the first quarter, to $ 6.22 millions, this is lower than Intellia Therapeutics, Inc.'s recent average Revenue surge of 249.75%.

Looking into first quarter results within Biotechnology & Drugs industry 7 other companies have achieved higher Revenue growth. While Intellia Therapeutics, Inc.' s Revenue doubling of 249.16% ranks overall at the positon no. 105 in the first quarter.



Revenue Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #8
Healthcare Sector #28
S&P 500 #105
Revenue Y/Y Growth Statistics
High Average Low
249.75 % 249.75 % 249.75 %
(Mar 31 2017)  

You need to upgrade your Flash Player

Other Revenue Growth
Biotechnology & Drugs Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NTLA's Revenue Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for NTLA's Competitors
Revenue Growth for Intellia Therapeutics,'s Suppliers
Revenue Growth for NTLA's Customers

You may also want to know
NTLA's Annual Growth Rates NTLA's Profitability Ratios NTLA's Asset Turnover Ratio NTLA's Dividend Growth
NTLA's Roe NTLA's Valuation Ratios NTLA's Financial Strength Ratios NTLA's Dividend Payout Ratio
NTLA's Roa NTLA's Inventory Turnover Ratio NTLA's Growth Rates NTLA's Dividend Comparisons



Companies with similar Revenue doubling for the quarter ending Mar 31 2017 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2017
Cytomx Therapeutics, Inc.  424.20 %$ 424.202 millions
Sientra, Inc.  409.11 %$ 409.109 millions
Sorrento Therapeutics, Inc.  393.32 %$ 393.320 millions
Bluebird Bio, Inc.  355.77 %$ 355.771 millions
Agenus Inc  352.36 %$ 352.365 millions
Protalix Biotherapeutics, Inc.  325.48 %$ 325.479 millions
Lifestyle Medical Network, Inc.  319.44 %$ 319.438 millions
Orexigen Therapeutics, Inc.  280.39 %$ 280.389 millions
Intellia Therapeutics, Inc.  249.75 %$ 249.747 millions
Biolargo, Inc.  230.06 %$ 230.060 millions
Corbus Pharmaceuticals Holdings, Inc.  226.20 %$ 226.199 millions
Exact Sciences Corp  226.01 %$ 226.006 millions
Accelerate Diagnostics, Inc.  225.15 %$ 225.153 millions
American Cryostem Corp  205.95 %$ 205.946 millions
Ionis Pharmaceuticals Inc  199.14 %$ 199.138 millions
Immune Design Corp.  193.34 %$ 193.344 millions
Transgenomic Inc  178.81 %$ 178.814 millions
Icu Medical Inc  175.71 %$ 175.710 millions
Novocure Ltd  167.22 %$ 167.218 millions
Invitae Corp  161.39 %$ 161.391 millions
Eagle Pharmaceuticals, Inc.  159.51 %$ 159.515 millions
Alnylam Pharmaceuticals, Inc.  158.13 %$ 158.135 millions
Catasys, Inc.  150.27 %$ 150.275 millions
Catalyst Biosciences, Inc.  148.62 %$ 148.624 millions
Viveve Medical, Inc.  136.84 %$ 136.838 millions
Flex Pharma, Inc.  134.72 %$ 134.724 millions
China Longyi Group International Holdings Ltd  126.39 %$ 126.388 millions


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2017 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com